Morgan Stanley analyst Vincent Andrews raised the firm’s price target on Chemours (CC) to $17 from $15 and keeps an Equal Weight rating on the shares. While the firm reduced its EBITDA forecasts, it increased its price target to reflect higher peer multiples.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC: